ES2103709T3 - Uso de inhibidores de peptidasa para la preparacion de medicamentos utiles en el tratamiento de la apoplejia. - Google Patents

Uso de inhibidores de peptidasa para la preparacion de medicamentos utiles en el tratamiento de la apoplejia.

Info

Publication number
ES2103709T3
ES2103709T3 ES89402762T ES89402762T ES2103709T3 ES 2103709 T3 ES2103709 T3 ES 2103709T3 ES 89402762 T ES89402762 T ES 89402762T ES 89402762 T ES89402762 T ES 89402762T ES 2103709 T3 ES2103709 T3 ES 2103709T3
Authority
ES
Spain
Prior art keywords
alpha
amino acid
group
peptidase
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89402762T
Other languages
English (en)
Inventor
Philippe Bey
Michael Angelastro
Shujaath Mehdi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2103709T3 publication Critical patent/ES2103709T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

EL INVENTO SE REFIERE A ANALOGOS DE SUSTRATOS DE PEPTIDASA EN LOS CUALES EL ATOMO DE HIDROGENO DEL GRUPO DE AMIDO DE SICILO DEL PEPTIDO DEL SUSTRATO HA SIDO REEMPLAZADO POR H O SUSTITUIDO POR UNA MOLECULA CARBONIL. ESTOS ANALOGOS DE LOS SUSTRATOS DE PEPTIDASA SUMINISTRAN INHIBIDORES DE ENZIMA ESPECIFICOS PARA UNA VARIEDAD DE PROTEASAS, LA INHIBICION DE LAS CUALES TENDRAN CONSECUENCIAS PSICOLOGICAS UTILES EN UNA VARIEDAD DE ESTADOS DE DISASIA.
ES89402762T 1988-10-07 1989-10-06 Uso de inhibidores de peptidasa para la preparacion de medicamentos utiles en el tratamiento de la apoplejia. Expired - Lifetime ES2103709T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25476288A 1988-10-07 1988-10-07

Publications (1)

Publication Number Publication Date
ES2103709T3 true ES2103709T3 (es) 1997-10-01

Family

ID=22965502

Family Applications (2)

Application Number Title Priority Date Filing Date
ES89402763T Expired - Lifetime ES2118710T3 (es) 1988-10-07 1989-10-06 Nuevos inhibidores de peptidasa.
ES89402762T Expired - Lifetime ES2103709T3 (es) 1988-10-07 1989-10-06 Uso de inhibidores de peptidasa para la preparacion de medicamentos utiles en el tratamiento de la apoplejia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES89402763T Expired - Lifetime ES2118710T3 (es) 1988-10-07 1989-10-06 Nuevos inhibidores de peptidasa.

Country Status (18)

Country Link
EP (2) EP0363284B1 (es)
JP (2) JP3203579B2 (es)
KR (2) KR900006362A (es)
CN (2) CN1041951A (es)
AT (2) ATE153029T1 (es)
AU (1) AU617875B2 (es)
CA (2) CA2000342C (es)
DE (2) DE68928042T2 (es)
DK (2) DK494789A (es)
ES (2) ES2118710T3 (es)
FI (2) FI894747A (es)
GR (1) GR3024158T3 (es)
HU (2) HUT54105A (es)
IL (2) IL91895A0 (es)
NO (2) NO894014L (es)
NZ (2) NZ230893A (es)
PT (2) PT91926B (es)
ZA (2) ZA897515B (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510531A (en) * 1989-04-10 1996-04-23 Suntory Limited Proteinase inhibitor
EP0423358A4 (en) * 1989-04-15 1992-05-06 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Postostatin and related compound thereof, or their salts
IL97428A0 (en) * 1990-03-05 1992-06-21 Cephalon Inc Chymotrypsin-like proteases and their inhibitors
GB9019558D0 (en) * 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
HU217612B (hu) * 1991-05-23 2000-03-28 Merrel Dow Pharmaceuticals Inc. Eljárás elasztáz és katepszin G inhibitor hatású peptidek előállítására
CA2071621C (en) * 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
US5650508A (en) * 1991-12-27 1997-07-22 Georgia Tech Research Corporation Peptide ketoamides
US6235929B1 (en) 1991-12-27 2001-05-22 Georgia Tech Research Corporation Tripeptide α-ketoamides
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
EP0610744B1 (en) * 1993-02-09 1998-11-04 Bayer Corporation Sulfonamide aminomethylene derivatives as immunosuppressants
US5672582A (en) * 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
US5541290A (en) * 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
EP0639585A1 (en) * 1993-08-20 1995-02-22 Banyu Pharmaceutical Co., Ltd. Elastase inhibitor
US5977074A (en) * 1993-10-01 1999-11-02 Merrell Pharmaceuticals, Inc. Inhibitors of β-amyloid protein production
IT1270882B (it) * 1993-10-05 1997-05-13 Isagro Srl Oligopeptidi ad attivita' fungicida
US6060462A (en) * 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
DE4421884A1 (de) 1994-06-23 1996-01-04 Hoechst Ag Verfahren zur Herstellung von Hydroxycarbonsäureaniliden
US5510369A (en) * 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
DE4427837A1 (de) 1994-08-05 1996-02-08 Hoechst Ag Verfahren zur Herstellung von O-Acylglykolsäureaniliden
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5691368A (en) * 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
NO315930B1 (no) * 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
MX9705449A (es) * 1995-01-18 1998-02-28 Alteon Inc Uso de compuestos de tiazolio para evitar y revertir la formacion de productos finales de glicosilacion avanzada.
DE19504225A1 (de) 1995-02-09 1996-08-14 Hoechst Ag Verfahren zur Herstellung von O-Acyloxycarbonsäureaniliden
NZ302649A (en) * 1995-02-17 2000-01-28 Basf Ag Dipeptide amidine derivatives, preparation and pharmaceutical compositions thereof
US5629324A (en) * 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
US6046169A (en) * 1995-06-07 2000-04-04 Cor Therapeutics, Inc. Inhibitors of factor XA
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5919765A (en) * 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
US6022861A (en) * 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
US6211154B1 (en) 1995-06-07 2001-04-03 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
US5827877A (en) * 1995-09-14 1998-10-27 Cephalon, Inc. Ketomethylene group-containing cysteine and serine protease inhibitors
US5723580A (en) * 1995-09-14 1998-03-03 Cephalon, Inc. Ketomethylene group-containing aldehyde cysteine and serine protease inhibitors
US5763576A (en) * 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
ES2186807T3 (es) * 1995-10-24 2003-05-16 Merck & Co Inc Inhibidores de trombina.
KR100490807B1 (ko) * 1995-11-28 2005-10-14 세파론, 인코포레이티드 시스테인및세린프로테아제의d-아미노산함유억제제
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
US6245743B1 (en) 1996-06-05 2001-06-12 Cor Therapeutics, Inc. Inhibitors of factor Xa
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
US5792761A (en) * 1996-08-12 1998-08-11 Merck & Co., Inc. Thrombin inhibitors
JP4199309B2 (ja) * 1996-09-06 2008-12-17 日本化薬株式会社 新規アセトアミド誘導体およびプロテアーゼ阻害
SI0932617T1 (en) * 1996-10-18 2002-06-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
EP2409985A3 (en) 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
US5798377A (en) * 1996-10-21 1998-08-25 Merck & Co., Inc. Thrombin inhibitors
DE19648793A1 (de) 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
WO1998038990A1 (en) * 1997-03-07 1998-09-11 Hoechst Marion Roussel, Inc. Method of treating trauma associated with brain, spinal cord or peripheral nerve injury using carbobenzyloxy n-protected di- and tripeptide phenylalaninals
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
US6011047A (en) * 1997-11-26 2000-01-04 Corvas International Inc. Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors
AU751412B2 (en) * 1997-11-26 2002-08-15 3-Dimensional Pharmaceuticals, Inc. Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
US6204384B1 (en) 1997-11-26 2001-03-20 Corvas International, Inc. Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors (II)
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
CA2317761A1 (en) 1998-01-26 1999-07-29 Basf Aktiengesellschaft Thrombin inhibitors
JP2002501889A (ja) 1998-02-02 2002-01-22 トラスティーズ オブ タフツ カレッジ グルコース代謝を調節する方法、およびそれに関連する試薬
US6204263B1 (en) 1998-06-11 2001-03-20 3-Dimensional Pharmaceuticals, Inc. Pyrazinone protease inhibitors
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
WO2000042059A1 (en) 1999-01-13 2000-07-20 Astrazeneca Ab New amidinobenzylamine derivatives and their use as thrombin inhibitors
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
WO2000073302A1 (en) 1999-05-27 2000-12-07 3-Dimensional Pharmaceuticals, Inc. Oxazaheterocycles as protease inhibitors
WO2001004117A1 (en) 1999-07-09 2001-01-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl protease inhibitors and diagnostic imaging agents
US6630510B1 (en) * 1999-10-28 2003-10-07 Merck & Co., Inc. Substituted succinic acid metallo-β-lactamase inhibitors and their use in treating bacterial infections
US6809092B2 (en) * 2000-01-26 2004-10-26 Ono Pharmaceutical Co., Ltd. Benezene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
AU2001265094A1 (en) 2000-06-01 2001-12-11 Merck And Co., Inc. Pyrazinone thrombin inhibitors
US6476016B2 (en) 2000-07-17 2002-11-05 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine pyrazinones as protease inhibitors
HUP0303358A3 (en) * 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
DK1385870T3 (da) 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2001277242A1 (en) 2000-08-04 2002-02-18 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine protease inhibitors
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
US6528503B2 (en) 2000-12-18 2003-03-04 Merck & Co., Inc. Thrombin inhibitors
AU2002230836A1 (en) 2000-12-18 2002-07-01 Merck & Co., Inc. Benzylamine derivatives and their use as thrombin inhibitors
US7144899B2 (en) 2001-02-09 2006-12-05 Merck & Co., Inc. Thrombin inhibitors
US6610701B2 (en) 2001-02-09 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US6777431B2 (en) 2001-07-13 2004-08-17 Corvas International, Inc. Non-convalent thrombin inhibitors
CA2466870A1 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
US7084134B2 (en) 2002-05-02 2006-08-01 Merk & Co., Inc. Thrombin inhibitors
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
GB0217136D0 (en) 2002-07-24 2002-09-04 Renovo Ltd Wound healing & treatment of fibrosis
CA2504933C (en) 2002-11-06 2012-10-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
US20050014747A1 (en) 2003-04-18 2005-01-20 Emily Reinhard Dihydrothiazine prodrugs of thiazolium agents
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7795205B2 (en) 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
AU2006302728B2 (en) 2005-10-07 2012-03-08 Molecular Discovery Systems Sumoylation control agent and uses thereof
US8829209B2 (en) 2006-01-11 2014-09-09 Seikagaku Corporation Cycloalkylcarbonylamino acid ester derivative and process for producing the same
JP4047365B2 (ja) 2006-01-11 2008-02-13 生化学工業株式会社 シクロアルカンカルボキサミド誘導体及びその製造方法
JP3975226B2 (ja) 2006-01-11 2007-09-12 生化学工業株式会社 シクロアルキルカルボニルアミノ酸誘導体及びその製造方法
EP2007364A4 (en) 2006-04-07 2009-11-11 Biopharmica Ltd MODULATOR OF THE TRANSCRIPTION FACTOR
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
WO2014081618A1 (en) 2012-11-20 2014-05-30 Merck Sharp & Dohme Corp. Thrombin inhibitors
KR102455946B1 (ko) * 2017-08-02 2022-10-20 가부시키가이샤 히로시마 메탈 앤드 머시너리 분산기와, 슬러리 중 입자의 분산 방법 및 에멀젼 제조 방법
RU2020134124A (ru) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4920118A (es) * 1972-06-23 1974-02-22
JPS594415B2 (ja) * 1974-02-18 1984-01-30 帝人株式会社 Ｄ，ｌ−２− アミノ −１− ブタノ−ルノ コウガクブンカツホウ
JPS50142505A (es) * 1974-05-08 1975-11-17
HU177098B (en) * 1979-01-04 1981-07-28 Gyogyszerkutato Intezet Process for producing new peptidyl-n-carboxy-l-arginin-a
JPS55138389A (en) * 1979-04-14 1980-10-29 Denki Kagaku Kogyo Kk Preparation of amino alcohols
FR2537131B1 (fr) * 1980-04-17 1986-05-09 Roques Bernard Nouveaux derives d'acides amines et leur application therapeutique
JPS5754157A (en) * 1980-09-19 1982-03-31 Nippon Kayaku Co Ltd L-argininal derivative and its preparation
JPS58198296A (ja) * 1982-05-12 1983-11-18 Chisso Corp ｄ−２−アミノブタノ−ルの製造法
GB2124233B (en) * 1982-07-19 1985-09-18 Nat Res Dev Synthetic peptides and their preparation
DE3481913D1 (de) * 1983-04-27 1990-05-17 Ici America Inc Prolin-derivate.
GB8312339D0 (en) * 1983-05-05 1983-06-08 Austen B M Peptides
FR2546164B1 (fr) * 1983-05-16 1987-07-17 Centre Nat Rech Scient Nouveaux derives de peptides, leur preparation et leur application comme inhibiteurs de l'elastase
JPS59227851A (ja) * 1983-06-09 1984-12-21 Sankyo Co Ltd レニン阻害作用を有するペプチド類
CA1267499A (en) * 1983-07-12 1990-04-03 Cedric H. Hassall Peptide amides and aldehydes
DK34086A (da) * 1985-01-23 1986-07-24 Abbott Lab Peptidylaminodioler
ZA86746B (en) * 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
DE3789347D1 (de) * 1986-10-14 1994-04-21 Banyu Pharma Co Ltd 5-Substituierte Amino-4-hydroxy-pentansäure-Derivate und deren Verwendung.
MY103189A (en) * 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
FI89058C (fi) * 1987-02-27 1993-08-10 Yamanouchi Pharma Co Ltd Foerfarande foer framstaellning av som remin-inhibitorer anvaenda 2-(l-alanyl-l-histidylamino)-butanol-derivat
US4820691A (en) * 1987-06-24 1989-04-11 E. R. Squibb & Sons, Inc. Amino acid 1,2-diketo derivatives as renin inhibitors
US4913296A (en) * 1988-03-30 1990-04-03 Applied Power Inc. Storing and dispensing system
DE3827415A1 (de) * 1988-08-12 1990-02-15 Behringwerke Ag Peptidderivate, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
NO894014D0 (no) 1989-10-06
IL91895A0 (en) 1990-06-10
ZA897515B (en) 1990-06-27
CA2000340A1 (en) 1990-04-07
NO894014L (no) 1990-04-09
GR3024158T3 (en) 1997-10-31
ZA897514B (en) 1990-06-27
ES2118710T3 (es) 1998-10-01
EP0363284A3 (en) 1992-07-01
DE68928662T2 (de) 1998-11-26
DE68928042T2 (de) 1997-08-28
JPH02134398A (ja) 1990-05-23
DE68928662D1 (de) 1998-06-10
FI894748A0 (fi) 1989-10-06
KR900006363A (ko) 1990-05-08
PT91927B (pt) 1995-07-03
HU895247D0 (es) 1990-01-28
EP0364344A3 (en) 1991-09-11
CN1041950A (zh) 1990-05-09
CA2000342A1 (en) 1990-04-07
DK494789D0 (da) 1989-10-06
DK494789A (da) 1990-04-08
CA2000342C (en) 2000-10-03
EP0363284A2 (en) 1990-04-11
EP0364344B1 (en) 1998-05-06
FI894747A (fi) 1990-04-08
IL91896A0 (en) 1990-06-10
JP3203579B2 (ja) 2001-08-27
EP0363284B1 (en) 1997-05-14
PT91927A (pt) 1990-04-30
FI894747A0 (fi) 1989-10-06
DK494689A (da) 1990-04-08
NO894013L (no) 1990-04-09
DK494689D0 (da) 1989-10-06
EP0364344A2 (en) 1990-04-18
NZ230893A (en) 1992-01-29
FI894748A (fi) 1990-04-08
NZ230916A (en) 1992-02-25
PT91926A (pt) 1990-04-30
JPH02256654A (ja) 1990-10-17
NO894013D0 (no) 1989-10-06
PT91926B (pt) 1995-07-03
HUT54105A (en) 1991-01-28
HU895246D0 (en) 1990-01-28
CN1041951A (zh) 1990-05-09
AU4262589A (en) 1990-04-12
ATE165835T1 (de) 1998-05-15
KR900006362A (ko) 1990-05-08
AU4249189A (en) 1990-06-28
DE68928042D1 (de) 1997-06-19
AU617875B2 (en) 1991-12-05
ATE153029T1 (de) 1997-05-15
AU626918B2 (en) 1992-08-13

Similar Documents

Publication Publication Date Title
ES2103709T3 (es) Uso de inhibidores de peptidasa para la preparacion de medicamentos utiles en el tratamiento de la apoplejia.
EP0393457B1 (en) Proteinase inhibitor
MX9304970A (es) ACIDOS ß-AMINOALQUIL- Y ß-N-PEPTIDILAMINOALQUIL-BORONICOS.
ATE257517T1 (de) Interleukin 1-beta protease und ihre inhibitoren
CO4950618A1 (es) Inhibidores de proteasas
PE69099A1 (es) Inhibidores de proteasas
DK537589D0 (da) Renininhiberende peptidasesubstratanaloge, hydrater, isostere eller farmaceutisk acceptable salte deraf
ES2187063T3 (es) Derivados de azetidinona para el tratamiento de infecciones por hcmv.
AU1270402A (en) Peptide derivatives and their pharmaceutically acceptable salts, processes for preparation of both, and use thereof
ATE46347T1 (de) Immunostimulierende peptide.
WO2000078793A3 (en) Antimicrobial agents
AR004401A1 (es) Derivados de la tirosina, procedimiento para prepararlos y preparaciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 363284

Country of ref document: ES